IDYA (STOCKS)
IDEAYA Biosciences, Inc. Common Stock
$30.300000
+1.320000 (+4.55%)
Prev close: $28.980000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Yujiro S. Hata
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,876.27M
- Employees
- 131
- P/E (TTM)
- -18.92
- P/B (TTM)
- 2.72
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
9
Strong Buy
13
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.11 | $-1.01 | -0.1010 | -10.01% |
|
Dec 2025 (Q4)
|
$-0.94 | $-0.99 | +0.0469 | +4.75% |
|
Sep 2025 (Q3)
|
$1.33 | $-0.56 | +1.8857 | +339.34% |
|
Jun 2025 (Q2)
|
$-0.88 | $-0.81 | -0.0750 | -9.32% |
Financial Statements
| Revenues | $225.27M |
| Nonoperating Income/Loss | $43.41M |
| Operating Expenses | $408.74M |
| Depreciation and Amortization | $2.80M |
| Research and Development | $339.54M |
| Other Operating Expenses | $66.39M |
| Operating Income/Loss | -$183.47M |
| Income/Loss From Continuing Operations After Tax | -$140.06M |
| Income/Loss From Continuing Operations Before Tax | -$140.06M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$140.06M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$140.06M |
| Net Income/Loss Available To Common Stockholders, Basic | -$140.06M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.58 |
| Diluted Earnings Per Share | -$1.60 |
| Basic Average Shares | 265,731,575 |
| Diluted Average Shares | 266,895,672 |
| Assets | $1.03B |
| Current Assets | $696.11M |
| Noncurrent Assets | $334.24M |
| Fixed Assets | $8.63M |
| Other Non-current Assets | $325.61M |
| Liabilities | $93.08M |
| Current Liabilities | $64.83M |
| Accounts Payable | $20.74M |
| Wages | $6.23M |
| Other Current Liabilities | $37.87M |
| Noncurrent Liabilities | $28.25M |
| Equity | $937.27M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $937.27M |
| Liabilities And Equity | $1.03B |
| Net Cash Flow From Operating Activities | -$85.93M |
| Net Cash Flow From Operating Activities, Continuing | -$85.93M |
| Net Cash Flow From Investing Activities | $109.11M |
| Net Cash Flow From Investing Activities, Continuing | $109.11M |
| Net Cash Flow From Financing Activities | $4.82M |
| Net Cash Flow From Financing Activities, Continuing | $4.82M |
| Net Cash Flow | $28.00M |
| Net Cash Flow, Continuing | $28.00M |
| Comprehensive Income/Loss | -$142.14M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$142.14M |
| Other Comprehensive Income/Loss | $39.67M |
| Other Comprehensive Income/Loss Attributable To Parent | -$2.08M |